Renovaro Biosciences Buys AI-Driven BioSymetrics

Dow Jones

Feb 27, 2025

By Chris Wack

Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company.

Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research.

BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets.

Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.

The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 26, 2025 13:44 ET (18:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514520869"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514520869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514520869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514520869","market":"hk","top_or_hot":-1,"title":"Renovaro Biosciences Buys AI-Driven BioSymetrics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company. \n</p>\n<p>\n  Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research. \n</p>\n<p>\n  BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets. \n</p>\n<p>\n  Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions. \n</p>\n<p>\n  The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 13:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renovaro Biosciences Buys AI-Driven BioSymetrics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenovaro Biosciences Buys AI-Driven BioSymetrics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-27 02:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company. \n</p>\n<p>\n  Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research. \n</p>\n<p>\n  BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets. \n</p>\n<p>\n  Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions. \n</p>\n<p>\n  The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 13:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RENB","symbol_name":"Lunai Bioworks","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514520869","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514520869","pubTimestamp":1740595440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company.Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research.BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets.Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RENB":"Lunai Bioworks","BK4139":"生物科技"},"translate_title":"Renovaro Biosciences收购人工智能驱动的BioSymetrics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RENB":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company. \n\n\n  Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research. \n\n\n  BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets. \n\n\n  Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions. \n\n\n  The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 13:44 ET (18:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}